This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
=== 2000 census === As of the 2000 United States census there were 7,746 people, 2,630 households, and 2,161 families residing in the borough. The population density was 3,625.9 inhabitants per square mile (1,400.0/km2). There were 2,702 housing units at an average density of 1,264.8 per square mile (488.3/km2). The racial makeup of the borough was 78.05% White, 0.92% African American, 0.04% Native American, 18.64% Asian, 0.65% from other races, and 1.70% from two or more races. Hispanic or Latino of any race were 3.99% of the population. There were 2,630 households, out of which 40.6% had children under the age of 18 living with them, 71.1% were married couples living together, 8.5% had a female householder with no husband present, and 17.8% were non-families. 15.9% of all households were made up of individuals, and 9.7% had someone living alone who was 65 years of age or older. The average household size was 2.91 and the average family size was 3.26. In the borough the age distribution of the population shows 26.3% under the age of 18, 4.7% from 18 to 24, 26.4% from 25 to 44, 25.7% from 45 to 64, and 16.9% who were 65 years of age or older. The median age was 41 years. For every 100 females, there were 92.7 males. For every 100 females age 18 and over, there were 88.2 males. The median income for a household in the borough was $84,692, and the median income for a family was $96,245. Males had a median income of $61,194 versus $38,990 for females. The per capita income for the borough was $41,573.
Fluvoxamine is a potent selective serotonin reuptake inhibitor with around 100-fold affinity for the serotonin transporter over the norepinephrine transporter. It has negligible affinity for the dopamine transporter or any other site, with the sole exception of the σ1 receptor. It behaves as a potent agonist at this receptor and has the highest affinity (36 nM) of any SSRI for doing so. This may contribute to its antidepressant and anxiolytic effects and may also afford it some efficacy in treating the cognitive symptoms of depression. It increases concentrations of the neurosteroid allopregnanolone, which may also contribute to its anxiolytic effects. Unlike some other SSRIs, fluvoxamine's metabolites are pharmacologically neutral.
==== Remdesivir/interferon beta-1a ==== In August 2020, the NIAID started the Adaptive COVID‑19 Treatment Trial 3 (ACTT 3) to evaluate the safety and efficacy of a treatment regimen consisting of remdesivir plus interferon beta-1a for hospitalized adults who have a laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation.
Sources: en.wikipedia.org
== Therapeutic research and use == Antimicrobial peptides have been used as therapeutic agents; their use is generally limited to intravenous administration or topical applications due to their short half-lives. As of January 2018 the following antimicrobial peptides were in clinical use:
==== Adverse effect ==== The common early side effects of SSRIs include nausea and loose stool, which can be solved by discontinuing the treatment. Headache, dizziness, insomnia are the common early side effects as well. Sexual dysfunction, anorgasmia, erectile dysfunction, and reduced libido are common adverse side effects of SSRIs. Sometimes they may persist after the cessation of treatment. Withdrawal symptoms like dizziness, headache and flu-like symptoms (fatigue/myalgia/loose stool) may occur if SSRI is stopped suddenly. The brain is incapable of upregulating the receptors to sufficient levels especially after discontinuation of the drugs with short half-life like paroxetine. Both fluoxetine and its active metabolite have a long half-life therefore it causes the least withdrawal symptoms.
Their relationship is strained as Cain urges a firmer stance against the refugees and threats in town and threatens to take control from Jenna. The Homestead comes under direct attack and key residents are killed. Cain agitates the Homesteaders to turn against Jeff as Jeff questions Jenna's leadership. A radical religious sect in town led by a man called Father Burnham, who has a few congregants among the Homesteaders, claims Ian Ross promised their church a quarter of the Homestead's supplies in the event of a collapse. He allies with Masterson and Raven Rock to agitate outsiders against the Homesteaders. The city government engages in skirmishes with the Homesteaders to test their defenses. Tara becomes disillusioned with Jenna also and she and Jeff consider whether to try to take over the Homestead. They reach a breaking point after their son is injured by a snakebite. Masterson and Bing invite Jeff to join their side. Burnham tries to convince members of his congregation who are Homesteaders to turn against Jenna. As threats grow, the Homesteaders wrestle with moral choices as they try to prepare for an inevitable attack by Raven Rock. They try to recruit people from town to fight in exchange for food. Abe clashes with Jeff, who is trying to determine how best to lead his family. As the Homesteaders anticipate the impending attack, various members must decide whose side they are on and what they will do.
And that's the S&D Group." One of the assistants whose flats were searched (Giuseppe Meroni) works for the EPP member Lara Comi, and the EPP member Maria Spyraki was later also put under investigation by the European Public Prosecutor's Office (EPPO). The S&D Group commissioned an inquiry conducted from March to June 2023 by three independent experts: former MEP Richard Corbett, auditor and governance expert Jean-Pierre Garitte, and expert in economic criminal law Silvina Bacigalupo. They presented their initial report to the Group in July. It warned of a heightened risk of geostrategic interference and geostrategic corruption and warned that the EU institutions need to strengthen their resilience by updating their rules and procedures. It pointed out that the existing regulatory framework laying down ethical requirements for MEPs and staff is distributed over at least 27 different documents at various levels of the legal hierarchy, from treaty-level provisions to EU legislation, inter-institutional agreements, parliamentary rules of procedure, the MEP code of conduct and a range of decisions by the Parliament, its Bureau, the Conference of Presidents and the Secretary General. The report identified some 50 shortcomings in them, from gaps to contradictions, weak wording, unclear obligations and inadequate enforcement. This part of the report fed into the subsequent revision of the European Parliament's Rules of Procedure and the Code of Conduct for Members (see below) adopted in September 2023.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.